Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.

Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY.

Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):1017-23. doi: 10.1016/j.ijrobp.2012.02.020. Epub 2012 Apr 27.

2.

A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.

Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA, Fakiris AJ.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62. doi: 10.1016/j.ijrobp.2010.08.056. Epub 2010 Oct 29.

PMID:
21035956
3.

Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.

Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, Miyagi K, Norihisa Y, Mizowaki T, Nagata Y, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e545-9. doi: 10.1016/j.ijrobp.2012.01.018. Epub 2012 Mar 19.

4.

Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.

Kim TH, Cho KH, Pyo HR, Lee JS, Zo JI, Lee DH, Lee JM, Kim HY, Hwangbo B, Park SY, Kim JY, Shin KH, Kim DY.

Radiology. 2005 Apr;235(1):208-15. Epub 2005 Feb 9.

PMID:
15703313
5.

Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).

Chaudhuri AA, Binkley MS, Rigdon J, Carter JN, Aggarwal S, Dudley SA, Qian Y, Kumar KA, Hara WY, Gensheimer M, Nair VS, Maxim PG, Shultz DB, Bush K, Trakul N, Le QT, Diehn M, Loo BW Jr, Guo HH.

Radiother Oncol. 2016 Jun;119(3):454-60. doi: 10.1016/j.radonc.2016.05.007. Epub 2016 Jun 3.

PMID:
27267049
6.

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".

Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG, Roth JA.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1120-8. doi: 10.1016/j.ijrobp.2014.01.022.

PMID:
24661665
7.

Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.

Harder EM, Park HS, Chen ZJ, Decker RH.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):e353-e359. doi: 10.1016/j.prro.2016.01.015. Epub 2016 Feb 4.

PMID:
27156424
8.

Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.

Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG.

Radiat Oncol. 2012 Sep 10;7:152.

9.

Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.

Baker R, Han G, Sarangkasiri S, DeMarco M, Turke C, Stevens CW, Dilling TJ.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):190-5. doi: 10.1016/j.ijrobp.2012.03.041. Epub 2012 Aug 25.

PMID:
22929858
10.

Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.

Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, Rinehart J, McGarry RC.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1325-31. doi: 10.1016/j.ijrobp.2012.11.011. Epub 2012 Dec 19.

PMID:
23265574
11.

Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer.

Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG.

Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):89-94.

PMID:
10924976
12.

Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease.

Bahig H, Filion E, Vu T, Chalaoui J, Lambert L, Roberge D, Gagnon M, Fortin B, Béliveau-Nadeau D, Mathieu D, Campeau MP.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):367-74. doi: 10.1016/j.prro.2016.01.009. Epub 2016 Jan 26.

PMID:
27068780
13.

Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.

Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JD, Lin SH, Chang JY.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1226-35. doi: 10.1016/j.ijrobp.2016.01.065. Epub 2016 Mar 18.

PMID:
27209498
14.

Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.

Trovo M, Minatel E, Durofil E, Polesel J, Avanzo M, Baresic T, Bearz A, Del Conte A, Franchin G, Gobitti C, Rumeileh IA, Trovo MG.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1114-9. doi: 10.1016/j.ijrobp.2014.01.012.

PMID:
24661664
15.

A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.

Claude L, Pérol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF, Carrie C.

Radiother Oncol. 2004 May;71(2):175-81.

PMID:
15110451
16.

Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.

Nakamura M, Nishimura H, Nakayama M, Mayahara H, Uezono H, Harada A, Hashimoto N, Ejima Y, Ishihara T, Sasaki R.

Br J Radiol. 2016 Dec;89(1068):20160560. Epub 2016 Nov 2.

17.

Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.

Thibault I, Poon I, Yeung L, Erler D, Kim A, Keller B, Lochray F, Jain S, Soliman H, Cheung P.

Clin Oncol (R Coll Radiol). 2014 Nov;26(11):713-9. doi: 10.1016/j.clon.2014.06.018. Epub 2014 Jul 29.

PMID:
25085765
18.

Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.

Barriger RB, Fakiris AJ, Hanna N, Yu M, Mantravadi P, McGarry RC.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1381-6. doi: 10.1016/j.ijrobp.2009.09.030. Epub 2010 Mar 16.

PMID:
20231061
19.

Dose-volume factors predicting radiation pneumonitis in patients receiving salvage radiotherapy for postlobectomy locoregional recurrent non-small-cell lung cancer.

Uno T, Isobe K, Kawakami H, Ueno N, Kawata T, Yamamoto S, Sekine Y, Iyoda A, Iizasa T, Fujisawa T, Shigematsu N, Ito H.

Int J Clin Oncol. 2006 Feb;11(1):55-9.

PMID:
16508730
20.

Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs.

Bongers EM, Botticella A, Palma DA, Haasbeek CJ, Warner A, Verbakel WF, Slotman B, Ricardi U, Senan S.

Radiother Oncol. 2013 Oct;109(1):95-9. doi: 10.1016/j.radonc.2013.10.011. Epub 2013 Oct 31.

PMID:
24183862

Supplemental Content

Support Center